Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes MG to Initiate Domestic PI/II Trials for Collategene
August 2, 2012
- Torii Initiates PII/PIII Clinical Studies in Japan for Desensitization Therapy for House Dust Mite Induced Allergies
August 2, 2012
- Daiichi Sankyo’s Apr-Jun Sales Up 4.7%, Bolstered by Ranbaxy
August 1, 2012
- Iwasaki of Takeda Shows Confidence in Achieving Sales Target of Nesina with Rapid Growth
August 1, 2012
- Astellas, Tokyo Institute of Technology to Start Joint Drug Discovery Research for Neglected Tropical Diseases
July 31, 2012
- Shionogi Files NDA for Fixed-Dose Combination of Irbetan, Fluitran
July 31, 2012
- Nycomed Drives Up Takeda’s April-June Sales by 11.5%, but Operating Profits Decline
July 31, 2012
- Nearly 60% of Doctors Feel Generics Might Be Less Effective than Original Drugs: Survey
July 31, 2012
- Research Subsidiary of Eisai to Move to Kobe Strategic Zone
July 31, 2012
- Major Domestic Makers’ Vaccine Business Gains Momentum; Addition of New Vaccines to Public Vaccination Program Could Spark Debate Over Funding
July 31, 2012
- Afatinib Significantly Improves PFS in Japanese NSCLC Patients: BI Japan
July 31, 2012
- Kyowa Kirin Launches Apokyn for Parkinson’s Disease
July 31, 2012
- Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
- Takeda Resubmits NDAs to US FDA for Alogliptin
July 31, 2012
- DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
- Kyowa Kirin’s 1st Half Pharmaceuticals Business Log 9.2% Sales Rise, but Operating Profits Fall
July 30, 2012
- US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo
July 30, 2012
- Approval for Once-Monthly Aripiprazole Hits Snag in US: Otsuka
July 30, 2012
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…